1-(thiophene-2-yl)-3-(3-nitrophenyl)-2-propene-1-one | 13982-55-3

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: 1-(thiophene-2-yl)-3-(3-nitrophenyl)-2-propene-1-one
• 英文别名: 3-(3-nitrophenyl)-1-(thien-2-yl)prop-2-en-1-one；(2E)-3-(3-nitrophenyl)-1-(thiophen-2-yl)prop-2-en-1-one；(E)-3-(3-nitrophenyl)-1-thiophen-2-ylprop-2-en-1-one
• CAS: 13982-55-3；135950-58-2
• 化学式: C₁₃H₉NO₃S
• 分子量: 259.285
• InChiKey: YNTQJIBSFGNMIH-VOTSOKGWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  91.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-[2-oxo-2-(thiophen-2-yl)ethyl]pyridinium iodide 、 1-(thiophene-2-yl)-3-(3-nitrophenyl)-2-propene-1-one 在 ammonium acetate 、 溶剂黄146 作用下， 以40%的产率得到4-(3-nitrophenyl)-2,6-di(2-thienyl)pyridine
  参考文献：
  名称：

  环亚铵盐的研究：一些新的2,4,6-三取代吡啶的合成。2个

  摘要：

  DOI：

  10.1021/je60086a032
• 作为产物：
  描述：

  2-乙酰基噻吩 、 间硝基苯甲醛 以 neat (no solvent) 为溶剂， 生成 1-(thiophene-2-yl)-3-(3-nitrophenyl)-2-propene-1-one
  参考文献：
  名称：

  Inhibitory potential of some chalcones on cathepsins B, H and L

  摘要：

  卡特普辛是细胞内蛋白酶，已知参与多种生理过程，如降解细胞外蛋白、前激素加工、动脉粥样硬化进展等。

  DOI：

  10.1039/c5ra12856k

文献信息

• A New and Direct Synthesis of Chalcones Via TFAA-H3PO4 Mediated C-C Bond Forming Reaction
  作者：Kavitha Kankanala、Lingam Venkata Reddy、Vangala Ranga Reddy、Khagga Mukkanti、Sarbani Pal

  DOI：10.2174/157017811794557750

  日期：2011.1.1

  A number of α,β-unsaturated carboxylic acids were reacted with electron rich arenes or heteroarene in the presence of trifluoroacetic anhydride (TFAA) and H3PO4 at room temperature to give a variety of chalcone derivatives in good to excellent yields. The methodology was used to prepare novel compounds of potential pharmacological significances.

  多种α,β-不饱和羧酸与富电子的芳烃或杂芳烃在三氟乙酸酐（TFAA）和磷酸（H3PO4）存在下，于室温反应，以良好至优秀的产率合成了多种查耳酮衍生物。该方法学被用于制备具有潜在药理学意义的创新化合物。
• Simple, Rapid and Reliable Preparation of [11C]-(+)-a-DTBZ of High Quality for Routine Applications
  作者：Jinming Zhang、Xiaojun Zhang、Yungang Li、Jiahe Tian

  DOI：10.3390/molecules17066697

  日期：——

  [11C]-(+)-a-DTBZ has been used as a marker of dopaminergic terminal densities in human striatum and expressed in islet beta cells in the pancreas. We aimed to establish a fully automated and simple procedure for the synthesis of [11C]-(+)-a-DTBZ for routine applications. [11C]-(+)-a-DTBZ was synthesized from a 9-hydroxy precursor in acetone and potassium hydroxide with [11C]-methyl triflate and was purified by solid phase extraction using a Vac tC-18 cartridge. Radiochemical yields based on [11C]-methyl triflate (corrected for decay) were 82.3% ± 3.6%, with a specific radioactivity of 60 GBq/mmol. Time elapsed was less than 20 min from end of bombardment to release of the product for quality control.

  [11C]-(+)-a-DTBZ已被用作人类纹状体中多巴胺能终端密度的标记物，并在胰腺的胰岛β细胞中表达。我们旨在建立一个完全自动化和简单的程序，以合成[11C]-(+)-a-DTBZ，以便进行常规应用。[11C]-(+)-a-DTBZ是从一种9-羟基前体在丙酮和氢氧化钾的条件下与[11C]-甲基三氟甲磺酸酯合成的，并通过使用Vac tC-18柱的固相提取进行纯化。基于[11C]-甲基三氟甲磺酸酯（已校正衰减）的放射化学产率为82.3% ± 3.6%，具有60 GBq/mmol的比放射活性。从轰击结束到产品释放进行质量控制的时间少于20分钟。
• Inhibitory potential of some chalcones on cathepsins B, H and L
  作者：Shweta Garg、Neera Raghav

  DOI：10.1039/c5ra12856k

  日期：——

  Cathepsins, intracellular proteases, are known to be involved in a number of physiological processes such as degradation of extracellular proteins, prohormone processing, progressions of atherosclerosis etc.

  卡特普辛是细胞内蛋白酶，已知参与多种生理过程，如降解细胞外蛋白、前激素加工、动脉粥样硬化进展等。
• N-Containing heterocyclic compounds, processes for the preparation thereof and composition comprising the same
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0387070A2

  公开（公告）日：1990-09-12

  Compounds of the formula: wherein R¹ is aryl optionally substituted with substituent(s) selected from the group consisting of nitro, cyano, halogen, halo(lower)alkyl, lower alkoxy, lower alkylsulfonyl, lower alkylsulfonylamino, amino, lower alkanoyl, sulfamoyl and lower alkylsulfamoyl; or a heterocyclic group optionally substituted with substituent(s) selected from the group consisting of nitro, cyano, lower alkanoyl and hydroxy(lower)alkyl; R² is cyano; lower alkanoyl; carboxy; esterified carboxy; hydroxy(lower)alkyl; carbamoyl substituted with heterocyclic(lower)alkyl; amino optionally substituted with substituent(s) selected from the group consisting of heterocyclic(lower)alkanoyl and halo(lower)alkanoyl; or N-containing heterocycliccarbonyl optionally substituted with lower alkyl; R³ is lower alkyl; and R⁴ is aryl optionally substituted with substituent(s) selected from the group consisting of nitro, hydroxy and halogen; carboxy; esterified carboxy; a heterocyclic group; lower alkyl; or carbamoyl substituted with heterocyclic(lower)alkyl; provided that R⁴ is aryl substituted with substituent(s) selected from the group consisting of nitro and hydroxy ; carboxy; esterified carboxy; a heterocyclic group; lower alkyl; or carbamoyl substituted with heterocyclic(lower)alkyl; when R¹ is phenyl substituted with nitro, and its pharmaceutically acceptable salt. Processes for the preparation of these compounds are also described, together with pharmaceutical compositions containing the compounds as an active ingredient. The compounds are useful for the treatment of ischemic diseases and reperfusion injury, and as cardioprotective agents.

  式中的化合物： 其中，R¹是任选被选自硝基、氰基、卤素、卤代（低级）烷基、低级烷氧基、低级烷基磺酰基、低级烷基磺酰基氨基、氨基、低级烷酰基、氨基磺酰基和低级烷基氨基磺酰基组成的取代基取代的芳基；或任选被选自硝基、氰基、低级烷酰基和羟基（低级）烷基组成的取代基取代的杂环基团； R²是氰基；低级烷酰基；羧基；酯化羧基；羟基（低级）烷基；被杂环（低级）烷基取代的氨基甲酰基；任选被选自杂环（低级）烷酰基和卤代（低级）烷酰基组成的取代基取代的氨基；或任选被低级烷基取代的含 N 杂环羰基； R³ 是低级烷基 R⁴ 是芳基，可任选被选自以下组别的取代基取代：硝基、羟基和卤素；羧基；酯化羧基；杂环基团；低级烷基；或被杂环（低级）烷基取代的氨基甲酰基； R⁴是被选自硝基和羟基的取代基取代的芳基；羧基；酯化羧基；杂环基团；低级烷基；或被杂环（低级）烷基取代的氨基甲酰基；当R¹是被硝基取代的苯基时，以及其药学上可接受的盐。 此外，还介绍了制备这些化合物的工艺，以及含有这些化合物作为活性成分的药物组合物。这些化合物可用于治疗缺血性疾病和再灌注损伤，也可用作心脏保护剂。
• Dulawat, Shiv S.; Chundawat, Jagveer S.; Roy, Ravindra S., Journal of the Indian Chemical Society, 2010, vol. 87, # 8, p. 981 - 986
  作者：Dulawat, Shiv S.、Chundawat, Jagveer S.、Roy, Ravindra S.、Chundawat, Sumer S.、Verma

  DOI：——

  日期：——